InvestorsHub Logo
Followers 12
Posts 616
Boards Moderated 0
Alias Born 05/06/2016

Re: None

Tuesday, 06/21/2016 12:45:06 PM

Tuesday, June 21, 2016 12:45:06 PM

Post# of 232961
Gilead can play dumb even though they've already said CytoDyn is a legitimate threat to their HIV revenue stream:

http://marketstatsanalytics.com/gild_proscons3.html

In addition to the well-known presence of several competitors in the HCV market, a significant threat could arise in the HIV market if a major biotech firm acquires one of the small firms now working on alternatives to the HAART treatments sold by Gilead Sciences. An example is the treatment named PRO140, developed by CytoDyn

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News